Library selection and directed evolution approaches to engineering targeted viral vectors

Biotechnology and Bioengineering

Volumn 98, Issue 3, 2007, Pages 515-524

  Jang, Jae Hyung ^a   Lim, Kwang Il ^a   Schaffer, David V ^a  

^a University of California   (United States)

Author keywords

Adeno associated virus; Directed evolution; Gene therapy; Lentivirus; Library selection; Retrovirus; Targeting; Viral vectors

Indexed keywords

BIOACTIVITY; DISEASES; ITERATIVE METHODS; PATIENT TREATMENT; PEPTIDES; VECTORS; VIRUSES;

ADENO-ASSOCIATED VIRUSES; GENE THERAPY; LENTIVIRUSES; LIBRARY SELECTION; RETROVIRUSES; VIRAL VECTORS;

GENETIC ENGINEERING;

CELL SURFACE RECEPTOR; ENVELOPE PROTEIN; PEPTIDE; PROTEINASE; RETROVIRUS VECTOR; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; BINDING AFFINITY; CELL SPECIFICITY; ENGINEERING; EVOLUTION; FELINE LEUKEMIA VIRUS; GENE LIBRARY; GENE THERAPY; GENETIC TRANSDUCTION; INFECTION; MOLONEY LEUKEMIA ONCOVIRUS; RETROVIRUS; REVIEW; STRUCTURE ACTIVITY RELATION; VESICULAR STOMATITIS VIRUS;

DIRECTED MOLECULAR EVOLUTION; DNA, VIRAL; GENE LIBRARY; GENE TARGETING; GENETIC ENGINEERING; GENETIC VECTORS; VIRUSES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; LENTIVIRUS;

EID: 35048872289     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21541     Document Type: Review

References (94)

1. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. 2006. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther 14(1):97-106.
2. Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. 1999. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat Biotechnol 17(2):181-186.
3. Benedict CA, Tun RY, Rubinstein DB, Guillaume T, Cannon PM, Anderson WF. 1999. Targeting retroviral vectors to CD34-expressing cells: Binding to CD34 does not catalyze virus-cell fusion. Hum Gene Ther 10(4):545-557.
4. Berns KI, Linden RM. 1995. The cryptic life style of adeno-associated virus. Bioessays 17(3):237-245.
5. Boder ET, Wittrup KD. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15(6):553-557.
6. Buchholz CJ, Peng KW, Morling FJ, Zhang J, Cosset FL, Russell SJ. 1998. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol 16(10):951-954.
7. Bupp K, Roth MJ. 2002. Altering retroviral tropism using a random-display envelope library. Mol Ther 5(3):329-335.
8. Bupp K, Roth MJ. 2003. Targeting a retroviral vector in the absence of a known cell-targeting ligand. Hum Gene Ther 14(16):1557-1564.
9. Bupp K, Sarangi A, Roth MJ. 2005. Probing sequence variation in the receptor-targeting domain of feline leukemia virus envelope proteins with peptide display libraries. J Virol 79(3):1463-1469.
10. Bupp K, Sarangi A, Roth MJ. 2006. Selection of feline leukemia virus envelope proteins from a library by functional association with a murine leukemia virus envelope. Virology 351(2):340-348.
11. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P, Deist FL, Fischer A. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288(5466):669-672.
12. Cepko CL, Roberts BE, Mulligan RC. 1984. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 37(3): 1053-1062.
13. Chiorini JA, Kim F, Yang L, Kotin RM. 1999. Cloning and characterization of adeno-associated virus type 5. J Virol 73(2):1309-1319.
14. Cosset FL, Morling FJ, Takeuchi Y, Weiss RA, Collins MK, Russell SJ. 1995. Retroviral retargeting by envelopes expressing an N-terminal binding domain. J Virol 69(10):6314-6322.
15. Cronin J, Zhang XY, Reiser J. 2005. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5(4):387-398.
16. Curran S, Murray GI. 1999. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189(3):300-308.
17. Daugherty PS, Chen G, Iverson BL, Georgiou G. 2000. Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies. Proc Natl Acad Sci USA 97(5):2029-2034.
18. Dong JY, Fan PD, Frizzell RA. 1996. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7(17):2101-2112.
19. Dwyer MA, Looger LL, Hellinga HW. 2004. Computational design of a biologically active enzyme. Science 304(5679):1967-1971.
20. Fields BN, Knipe DM, Howley PM, Griffin DE. 2001. Fields virology. Philadelphia: Lippincott Williams & Wilkins. 2 v. (xix, 3087, I-72) p.
21. Fisher KJ, Jooss K, Alston J, Yang Y, Haecker SE, High K, Pathak R, Raper SE, Wilson JM. 1997. Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3(3):306-312.
22. Flannery JG, Zolotukhin S, Vaquera MI, LaVail MM, Muzyczka N, Hauswirth WW. 1997. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 94(13):6916-6921.
23. Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ, Humphries M. 2004. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 15(1):93-128.
24. Ghosh D, Barry MA. 2005. Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J Virol 79(21):13667-13672.
25. Girod A, Ried M, Wobus C, Lahm H, Leike K, Kleinschmidt J, Deleage G, Hallek M. 1999. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2. Nat Med 5(9):1052-1056.
26. Glasgow JN, Everts M, Curiel DT. 2006. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 13(9):830-844.
27. Grifman M, Trepel M, Speece P, Gilbert LB, Arap W, Pasqualini R, Weitzman MD. 2001. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther 3(6):964-975.
28. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. 2000. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 74(2):992-996.
29. Harris LJ, Larson SB, Hasel KW, Day J, Greenwood A, McPherson A. 1992. The three-dimensional structure of an intact monoclonal antibody for canine lymphoma. Nature 360(6402):369-372.
30. Hartl I, Schneider RM, Sun Y, Medvedovska J, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ. 2005. Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther 12(11):918-926.
31. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset FL. 1999. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther 10(9):1533-1544.
32. Hughes SM, Moussavi-Harami F, Sauter SL, Davidson BL. 2002. Viral-mediated gene transfer to mouse primary neural progenitor cells. Mol Ther 5(1):16-24.
33. Isner JM, Asahara T. 1999. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 103(9):1231-1236.
34. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ. 1994. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8(2):148-154.
35. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW, Arruda V, Johnson F, Scallan C, Skarsgard E, Flake AW, High KA. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 24(3):257-261.
36. Kayman SC, Park H, Saxon M, Pinter A. 1999. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system. J Virol 73(3):1802-1808.
37. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kim DH. 2000. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6(8):879-885.
38. Li Y, Drone C, Sat E, Ghosh HP. 1993. Mutational analysis of the vesicular stomatitis virus glycoprotein G for membrane fusion domains. J Virol 67(7):4070-4077.
39. Magnusson MK, Hong SS, Henning P, Boulanger P, Lindholm L. 2002. Genetic retargeting of adenovirus vectors: Functionality of targeting ligands and their influence on virus viability. J Gene Med 4(4):356-370.
40. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. 2006. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24(2):198-204.
41. Mann R, Mulligan RC, Baltimore D. 1983. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33(1):153-159.
42. Marquart M, Deisenhofer J, Huber R, Palm W. 1980. Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 A and 1.0 A resolution. J Mol Biol 141(4):369-391.
43. Marshall E. 2000. Genome sequencing. Claim and counterclaim on the human genome. Science 288(5464):242-243.
44. Martinez I, Wertz GW. 2005. Biological differences between vesicular stomatitis virus Indiana and New Jersey serotype glycoproteins: Identification of amino acid residues modulating pH-dependent infectivity. J Virol 79(6):3578-3585.
45. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. 2002. RNA interference in adult mice. Nature 418(6893):38-39.
46. McKirnan MD, Guo G, Waldman LK, Dalton N, Lai NC, Gao MH, Roth DA, Hammond HK. 2000. Intracoronary gene transfer of fibroblast growth factor-4 increases regional contractile function and responsiveness to adrenergic stimulation in heart failure. Cardiac Vasc Regen 1.
47. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, Ragni MV, Manno CS, Sommer J, Jiang H, Pierce GF, Ertl HC, High KA. 2007. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13(4):419-422.
48. Morgan RA, Anderson WF. 1993. Human gene therapy. Annu Rev Biochem 62:191-217.
49. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD. 2000. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J Virol 74(4):1761-1766.
50. Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D, Milla C, Brody AS, Clancy JP, Ramsey B, Hamblett N, Heald AE. 2004. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, double-blind, placebo-controlled trial. Chest 125(2):509-521.
51. Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, Trepel M. 2003. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 21(9):1040-1046.
52. Mulligan RC. 1993. The basic science of gene therapy. Science 260(5110): 926-932.
53. Muzyczka N, Warrington KH Jr. 2005. Custom adeno-associated virus capsids: The next generation of recombinant vectors with novel tropism. Hum Gene Ther 16(4):408-416.
54. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272(5259):263-267.
55. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, Hacker U, Thrasher AJ, Ali RR, Hallek M, Baker AH. 2001. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 4(3):174-181.
56. Nicklin SA, White SJ, Nicol CG, Von Seggern DJ, Baker AH. 2004. In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J Gene Med 6(3):300-308.
57. Opie SR, Warrington KH, Aqbandje-McKenna M, Zolotukhin S, Muzyczka N. 2003. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol 77(12):6995-7006.
58. Patterson SM, Swainsbury R, Routiedge EG. 1999. Antigen-specific membrane fusion mediated by the haemagglutinin protein of influenza A virus: Separation of attachment and fusion functions on different molecules. Gene Ther 6(4):694-702.
59. Perabo L, Buning H, Kofler DM, Ried MU, Girod A, Wendtner CM, Enssle J, Hallek M. 2003. In vitro selection of viral vectors with modified tropism: The adeno-associated virus display. Mol Ther 8(1): 151-157.
60. Perabo L, Endell J, King S, Lux K, Goldnau D, Hallek M, Buning H. 2006. Combinatorial engineering of a gene therapy vector: Directed evolution of adeno-associated virus. J Gene Med 8(2):155-162.
61. Pereboev A, Pereboeva L, Curiel DT. 2001. Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation. J Virol 75(15):7107-7113.
62. Ponnazhagan S, Wang XS, Woody MJ, Luo F, Kang LY, Nallari ML, Munshi NC, Zhou SZ, Srivastava A. 1996. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: Human megakaryocyte leukaemia cells are non-permissive for AAV infection. J Gen Virol 77(Pt 6):1111-1122.
63. Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M Jr. 2002. Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol 76(24): 12900-12907.
64. Powell SK, Kaloss MA, Pinkstaff A, McKee R, Burimski I, Pensiero M, Otto E, Stemmer WP, Soong NW. 2000. Breeding of retroviruses by DNA shuffling for improved stability and processing yields. Nat Biotechnol 18(12):1279-1282.
65. Reynolds PN, Zinn KR, Gavrilyuk VD, Balyasnikova IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizzle WE, Douglas JT, Danilov SM, Curiel DT. 2000. A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2(6):562-578.
66. Robson T, Hirst DG. 2003. Transcriptional targeting in cancer gene therapy. J Biomed Biotechnol 2003(2):110-137.
67. Roche S, Rey FA, Gaudin Y, Bressanelli S. 2007. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315(5813):843-848.
68. Romano G. 2004. Systems for regulated or tissue-specific gene expression. Drug News Perspect 17(2):85-90.
69. Rothenberg SM, Olsen MN, Laurent LC, Crowley RA, Brown PO. 2001. Comprehensive mutational analysis of the Moloney murine leukemia virus envelope protein. J Virol 75(23):11851-11862.
70. Russell SJ, Cosset FL. 1999. Modifying the host range properties of retroviral vectors. J Gene Med 1(5):300-311.
71. Russell SJ, Hawkins RE, Winter G. 1993. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21(5):1081-1085.
72. Samulski RJ, Chang LS, Shenk T. 1989. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol 63(9):3822-3828.
73. Schlchuber LD, Rose JK. 2004. Prediction and identification of a permissive epitope insertion site in the vesicular stomatitis virus glycoprotein. J Virol 78(10):5079-5087.
74. Schneider RM, Medvedovska Y, Hartl I, Voelker B, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ. 2003. Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases. Gene Ther 10(16):1370-1380.
75. Shi W, Arnold GS, Bartlett JS. 2001. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther 12(14):1697-1711.
76. Smith GP. 1985. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228(4705):1315-1317.
77. Smith-Arica JR, Thomson AJ, Ansell R, Chiorini J, Davidson B, McWhir J. 2003. Infection efficiency of human and mouse embryonic stem cells using adenoviral and adeno-associated viral vectors. Cloning Stem Cells 5(1):51-62.
78. Snitkovsky S, Young JA. 1998. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc Natl Acad Sci USA 95(12):7063-7068.
79. Soong NW, Nomura L, Pekrun K, Reed M, Sheppard L, Dawes G, Stemmer WP. 2000. Molecular breeding of viruses. Nat Genet 25(4): 436-439.
80. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, Faldella A, Rege-Cambrin G, Thunberg U, Nilsson K, Caligaris-Cappio F. 1999. MEC1 and ME C2:two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 23(2):127-136.
81. Stemmer WP. 1994. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370(6488):389-391.
82. Sun JY, Anand-Jawa V, Chatterjee S, Wong KK. 2003. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 10(11):964-976.
83. Thomas CE, Storm TA, Huang Z, Kay MA. 2004. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78(6):3110-3122.
84. Verma IM, Somia N. 199/. Gene therapy - promises, problems and prospects. Nature 389(6648):239-242.
85. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH. 2004. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109(4):513-519.
86. Wickham TJ, Segal DM, Roelvink PW, Carrion ME, Lizonova A, Lee GM, Kovesdi I. 1996. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 70(10):6831-6838.
87. Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA. 2000. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: Epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol 74(19):9281-9293.
88. Work LM, Nicklin SA, Brain NJ, Dishart KL, Von Seggern DJ, Hallek M, Buning H, Baker AH. 2004. Development of efficient viral vectors selective for vascular smooth muscle cells. Mol Ther 9(2):198-208.
89. Work LM, Buning H, Hunt E, Nicklin SA, Denby L, Britton N, Leike K, Odenthal M, Drebber U, Hallek M, Baker AH. 2006. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 13(4):683-693.
90. Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. 2000. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 74(18):8635-8647.
91. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS. 2002. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 99(16):10405-10410.
92. Yu JH, Schaffer DV. 2006a. High-throughput, library-based selection of a murine leukemia virus variant to infect nondividing cells. J Virol 80(18):8981-8988.
93. Yu JH, Schaffer DV. 2006b. Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. J Virol 80(7):3285-3292.
94. Zhao H, Arnold FH. 1997. Optimization of DNA shuffling for high fidelity recombination. Nucleic Acids Res 25(6):1307-1308.